SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is experiencing significant downward pressure as investors rotate out of precious metals due to a stronger dollar, rising Treasury yields, and persistent inflation concerns following the U.S.-Iran conflict. The community is actively debating whether this decline represents a major liquidity-driven capitulation or a temporary pullback, with many participants split between aggressively buying the dip for long-term protection against debt and stagflation, or exiting positions amid heightened market volatility.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer Inc. is experiencing extreme volatility and intense community debate following a federal indictment alleging that a co-founder and employees engaged in a multi-billion dollar scheme to smuggle AI servers to China. While bulls emphasize that the company itself was not named as a defendant and point to its strong revenue growth as a buying opportunity, bears and skeptical investors argue that the management's involvement in a national security breach creates irreparable reputational damage and threatens future partnerships with key players like Nvidia.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

The SPY is experiencing significant volatility as investors weigh the impact of an escalating geopolitical standoff in the Strait of Hormuz against the potential for an impending peace deal. Community sentiment is deeply fractured, with bears highlighting recession risks and inflationary pressures, while bulls and contrarians are closely monitoring the market for signs of a technical bounce or a larger squeeze.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna Inc. (ANNA) is surging as geopolitical instability in the Middle East triggers significant supply shocks in the global liquefied natural gas market. Investors are closely monitoring the stock due to its strategic positioning in Italian natural gas assets and high trading volume, fueling active community debate regarding potential short-squeeze dynamics and the impact of the unfolding energy crisis.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is facing significant downward pressure as investors react to a combination of geopolitical instability, shifting macro-economic signals, and a federal jury ruling that Musk misled investors during the 2022 Twitter acquisition. The community is sharply divided, with bulls pointing to the potential long-term value of the new Terafab chip initiative and robotics, while bears are aggressively highlighting deteriorating sales, regulatory investigations, and the risk that the stock is caught in a broader market correction.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending as investors await a critical Supreme Court decision regarding patent infringement that could reshape 'skinny label' drug regulations. Meanwhile, community sentiment is heavily focused on the company's recent move toward profitability and anticipation that its cash-positive position and intellectual property might attract potential acquisition interest during the J.P. Morgan Healthcare Conference.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Invesco QQQ Trust is experiencing heightened volatility as the market reacts to a 48-hour ultimatum issued by the U.S. government regarding the Strait of Hormuz. The investor community is actively debating the geopolitical risks, potential for an energy sector shock, and the broader implications for the 401k-heavy tech sector as traders weigh the credibility of these evolving threats against recent market overselling.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is capturing significant market attention following a high-profile feature on '60 Minutes' that highlighted the company's strategic importance in securing U.S. rare earth supply chains. Investors and community members are actively debating the stock's role in national security and the broader rare earth supercycle as the company transitions into a fully integrated manufacturer.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is seeing high volatility as traders react to shifting weather models, ongoing Middle East geopolitical tensions, and uncertainty regarding natural gas storage levels. The community is actively debating the impact of potential supply disruptions in the Strait of Hormuz versus bearish seasonal trends as the market approaches the spring shoulder season.

AABG Token

AABBG is trending as shareholders rally around the anticipation of the new AABB Wallet launch and the debut of the silver-backed AABBS token, while maintaining high conviction in their legal battle against market makers for alleged price manipulation. The community remains focused on the company's reported gold and silver stockpiles, with many long-term investors actively accumulating shares and discussing the potential for a significant short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech Microcap Rockets After Securing Major Capital Infusion at Premium Valuation

The biotechnology sector continues to reward companies that successfully secure funding to advance late-stage clinical programs, particularly when those financings are completed at premiums to market. In an environment where capital efficiency and clear regulatory pathways are critical, investors are closely watching which companies can extend their runway while positioning themselves for meaningful clinical milestones.Shares of Serina Therapeutics, Inc. (NYSE American: SER) are surging Wednesday after the company announced a private placement financing that could bring in up to $30 ...

AI Ambitions, Autonomous Bets, and Deal Drama

Wall Street is navigating a crosscurrent of aggressive AI pivots and long-dated autonomy bets, as companies across sectors reposition for what looks like a more competitive, and more technologically driven, cycle ahead. $UBER, $RIVN, $TGNT, $CHNR, $SER, $TWO, $UWMC

<ul class="summary-bullets"><li>The clearance allows the clinical-stage biotech firm to move ahead with preparations for a planned Phase 1b registrational study.</li><li>Serina&nbsp;had previously received written feedback from the agency supporting its proposed registrational trial design under an NDA pathway.</li><li>The latest update follows a setback in November 2025, when the FDA placed a clinical hold on the application to initiate clinical trials.</li></ul>Shares of Serina Therapeutics (SER) surged more than 70% in pre-market trading on Thursday after the company announced that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for SER-252, a therapy to treat patients with Parkinson’s disease.SER-252 is an experimental apomorphine-based therapy to provide continuous dopaminergic stimulation, an approach shown to ease levodopa-related motor complications such as dyskinesia in people with Parkinson’s disease.<a href="https://stocktwits.com/symbol/SER">SER stock</a> had surged nearly 35% in after-hours trading on Wednesday.<h2 class="st-heading-2">SER-252: What Next?</h2>The clearance allows the clinical-stage biotech firm to move ahead with preparations for a planned Phase 1b registrational study in patients with advanced Parkinson’s disease. The IND clearance follows extensive regulatory engagement between Serina and the FDA.The company previously received written feedback from the agency supporting its proposed registrational trial design under an NDA pathway.“With FDA alignment on a registrational development strategy under a 505(b)(2) NDA pathway, we believe SER-252 has a clear and efficient path forward toward addressing a significant unmet medical need,” said Steve Ledger, Chief Executive Officer of Serina Therapeutics.The latest update follows a setback in November 2025, when the FDA placed a clinical hold on Serina’s application to initiate clinical trials. That hold was tied to a request for additional information related to an excipient in the drug’s formulation, a non-active substance included in a drug formulation alongside the active ingredient. Serina emphasized that the FDA’s concerns did not involve SER-252’s active drug substance or its proposed mechanism of action.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bearish’ a day earlier, accompanied by ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/SER_jpg_f485987591.webp" alt="SER.jpg" width="927" height="114"><figcaption>SER's Sentiment Meter and Message Volumes in Premarket on Jan. 29, 2026 | Source: Stocktwits</figcaption></figure>One bullish user said the stock price could double with good volumes.<stembedurl>https://stocktwits.com/Targeted_Trading/message/643250368</stembedurl>Another user simply said “massive news”, and the stock could climb to $8. It is currently around $4.<stembedurl>https://stocktwits.com/madape/message/643249925</stembedurl>SER shares have shed more than 40% in the past year, though its year-to-date gains are over 25%.Read also: <a href="http://stocktwits.com/news-articles/markets/equity/nasdaq-sp500-futures-higher-meta-tsla-ser-mp-crml-stocks-to-watch/cmyidGCR4KJ">Nasdaq, S&amp;P 500 Futures Climb Ahead Of Apple Earnings: Why META, TSLA, MP, CRML, SER Are On Traders' Radar Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Did SER Stock Surge Over 70% In Pre-Market Today?

The U.S. Food and Drug Administration cleared its Investigational New Drug application for SER-252, a therapy to treat patients with Parkinson’s disease.

SER Stock Surges Over 70% Pre-Market After FDA Clears Path For Parkinson’s Therapy

Equity

<ul class="summary-bullets"><li>Wall Street weighed heavy earnings and lingering government shutdown concerns.</li><li>Meta’s upbeat outlook offset Microsoft’s cloud slowdown, shifting focus to Apple’s earnings later today.</li><li>Commodities surged, with gold and silver hitting fresh record highs.</li></ul>U.S. stock futures were higher early Thursday as investors parsed the earnings report from the first of the “Magnificent Seven” companies (Meta, Microsoft, and Tesla), with the focus shifting to Apple, which reports earnings later today.&nbsp;As of 3:00 a.m. ET on Thursday, Nasdaq futures were up 0.4%, S&amp;P 500 futures gained 0.3%, while the Dow and Russell 2000 futures were flat.&nbsp;&nbsp;Meanwhile, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, remained ‘extremely bearish’, amid high message volumes.&nbsp;Precious metals continued to notch fresh records, with gold surging near $5600 and silver past $120.&nbsp;<a href="https://stocktwits.com/symbol/GLD/">SPDR Gold Shares ETF (GLD)</a> was the top trending ticker on Stocktwits at the time of writing. The&nbsp;<a href="https://stocktwits.com/symbol/SLV">iShares Silver Trust (SLV)</a> also saw retail sentiment remaining in the ‘extremely bullish’ territory, with ‘extremely high’ levels of chatter. Among base metals, copper prices too have surged 9% this month.Trending Stocks To WatchApple (AAPL): Investors will be watching for its earnings report after the market closes, with an eye on iPhone demand commentary and updates to its AI roadmap.Western Digital (WDC),&nbsp;SanDisk (SNDK): Watch out for these data storage giants as they report earnings today.Meta Platforms (META), Microsoft (MSFT):&nbsp;Meta stock surged in after-hours, driven by a strong sales forecast and a $100-billion AI investment plan. On the other hand, Microsoft tumbled due to slowing cloud growth and soft margin guidance.Tesla (TSLA): CEO Elon Musk confirmed plans to discontinue two EV models as it pivots to robotics. Tesla has also warned that capital expenditures could exceed $20 billion in 2026.Critical Minerals (MP, UAMY, TMC, USAR, CRML): U.S. miner stocks were under pressure amid reports that the Trump administration was considering shelving plans for minimum price floors. MP Materials was one of the first companies to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-mp-uamy-tmc-usar-crml-stocks-dip-after-hours-today/cmyLvl0R40w">state</a> that the news was “inaccurate.”&nbsp;Carvana (CVNA): The stock plunged yesterday amid a high-profile short seller's accusations of overstated earnings.Alibaba (BABA): Its logistics arm reportedly plans to merge its autonomous driving unit with a Chinese ‘Robovan’ startup.Nvidia (NVDA):&nbsp;Faces renewed scrutiny after U.S. lawmakers raised concerns about its past involvement with China’s DeepSeek AI models.Home Depot (HD): Has announced layoffs of roughly 800 workers and mandated a full return to work-from-office.CRISPR Therapeutics (CRSP),&nbsp;Beam Therapeutics (BEAM):&nbsp;Cathie Wood’s ARK Investment Management has bought shares in these gene-editing stocks.Serina Therapeutics (SER): The stock surged in after-hours trading after the FDA cleared its Investigational New Drug (IND) application for a drug to treat advanced Parkinson’s disease.Other tickers trending on Stocktwits at the time of writing included ServiceNow (NOW), SoFi Technologies (SOFI), CrowdStrike Holdings (CRWD), and Novavax (NVAX), among others.&nbsp; Other Catalysts To Watch On the economic front, traders will monitor Initial Jobless Claims and the U.S. Trade Balance data today.And on the earnings radar, investors will also be watching for the quarterly reports from Mastercard (MA), Honeywell (HON), Caterpillar (CAT), and Comcast (CMCSA) before the markets open. After the close, investors will watch earnings from Visa, SAP, KLA, Deckers Brands, and Stryker, among others.For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Climb Ahead Of Apple Earnings: Why META, TSLA, MP, CRML, SER Are On Traders' Radar Today

 Retail sentiment on major ETFs such as SPY and QQQ remains ‘extremely bearish’ on Stocktwits. 

<ul class="summary-bullets"><li>The agency has requested more information regarding an excipient in the formulation of SER-252, the company said.&nbsp;</li><li>The company said that it intends to work with the FDA to address its concerns. &nbsp;</li></ul>Shares of Serina Therapeutics (SER) slumped 7% in the pre-market session on Monday after the company announced that the U.S. Food and Drug Administration (FDA) had placed a clinical hold on its application to initiate clinical trials for its advanced Parkinson’s disease therapy candidate.The agency has requested more information regarding an excipient in the formulation of SER-252, the company said. An excipient is a substance, other than the active pharmaceutical ingredient (API), that is deliberately included in a drug formulation.Serina<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/03/3178999/0/en/Serina-Therapeutics-Provides-Regulatory-Update-on-SER-252-Program.html"> noted</a> that the agency’s feedback does not relate to its active drug substance or its proposed action mechanism.<h2 class="st-heading-2">What Are The Steps Forward?</h2>The company said that it intends to work with the FDA to address its concerns. Serina expects to receive the FDA’s formal clinical-hold letter within 30 days and provide an update once it has aligned with the agency on the next steps.<blockquote>“We appreciate the FDA’s engagement and constructive feedback. We will provide the additional information requested promptly as we continue to move forward in the registrational trial for SER-252.”&nbsp; -Steve Ledger, CEO, Serina Therapeutics.</blockquote>Board Member of Serina and Co-Founder and Executive Chairman of Juvenescence, Greg Bailey, has pledged to continue supporting the company financially and strategically in the initiation of clinical trials for SER-252. The registrational study of SER-252 is designed to evaluate the safety, tolerability, and pharmacokinetics of subcutaneous SER-252 compared to placebo, and will be conducted across sites in the U.S. and Australia.“This update does not change our conviction in Serina’s long-term potential or our belief in SER-252’s ability to meaningfully improve the lives of patients with advanced Parkinson’s disease,” he added.<h2 class="st-heading-2"> How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SER">SER stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘high’ levels.SER stock is down 0.2% this year and approximately 22% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/vertiv-bets-1-billion-on-ai-infrastructure-buys-liquid-cooling-firm-purge-rite/cL2NPfzR3za">Vertiv Bets $1 Billion On AI Infrastructure, Buys Liquid-Cooling Firm PurgeRite</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

Serina Therapeutics Stock Slumps Pre-Market After FDA Places Hold On Application To Initiate Clinical Trials For Experimental Therapy

Serina noted that the agency’s feedback does not relate to its active drug substance or its proposed action mechanism.

Shares of Serina Therapeutics surged 37% in after-hours trading on Monday after the company said the U.S. Food and Drug Administration (FDA) supported advancing its Parkinson’s drug candidate SER-252 (POZ-apomorphine) into a registrational clinical program.The stock ended Monday’s session down 0.2% at $5.64, but surged 37.2% to $7.74 in after-hours trading following the FDA update.The FDA feedback followed a recent Type B meeting and paves the way for Serina to move forward with a streamlined regulatory strategy.“People living with advanced Parkinson’s need more consistent relief from motor fluctuations and our data to date suggest that SER-252 may reliably improve daily function,” CEO Steve Ledger said, adding that the company’s plan is designed to be both rigorous and capital efficient.The proposed program will leverage prior knowledge of apomorphine while incorporating Serina’s POZ-enabled profile. According to the FDA’s feedback, Serina’s first study could be designed as part of its overall registrational trial program, subject to final documentation at the time of IND submission.Serina plans to submit a U.S. IND application in the fourth quarter of 2025 and begin dosing patients in Australia later this year, with the data expected to feed into the global registrational package. U.S. patient enrollment is anticipated to begin in the first quarter of 2026, once the IND is cleared.The planned SER-252-1b study will test the therapy in up to 88 adults with Parkinson’s disease and motor fluctuations, evaluating safety, tolerability, pharmacokinetics, and exploratory efficacy measures, including MDS-UPDRS motor scores.SER-252 is designed to provide continuous dopaminergic stimulation (CDS) via once- or twice-weekly subcutaneous injections, utilizing Enable Injections’ enFuse wearable delivery platform to enhance patient comfort and convenience.&nbsp;Serina believes its POZ drug optimization technology can help stabilize drug levels and reduce side effects compared with traditional therapies.Ledger said the FDA’s response also validated Serina’s broader pipeline ambitions: “The feedback provides early proof-of-principle for our platform, confirming that we can effectively align with the agency’s expectations for the 505(b)(2) NDA pathway.”On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user suggested that Serina shares&nbsp;could continue to rise in the next session and said they were already “fully loaded.”<stembedurl>https://stocktwits.com/Santa34/message/626511634</stembedurl>Another user speculated whether Serina’s stock could reach $20 as soon as the next trading session.<stembedurl>https://stocktwits.com/darthttrader/message/626511005</stembedurl><a href="https://stocktwits.com/symbol/SER">Serina’s stock</a> has risen 12.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Serina’s stock (SER) has risen 12.6% so far in 2025. (Photo credit: Getty Images)

Why Did Serina Therapeutics Stock Rocket 37% After The Bell Today?

The FDA backed advancing its Parkinson’s drug candidate SER-252 into a registrational clinical program, a move that retail traders said could fuel further gains.

Shares of Serina Therapeutics, Inc. surged over 15% in pre-market trading on Tuesday, positioning the clinical-stage biotech&nbsp;stock to hit its highest level in over a month.&nbsp;The jump follows Serina’s announcement of a $10 million equity financing agreement with strategic shareholder JuvVentures (UK), aimed at propelling its SER-252 program for advanced Parkinson’s disease into clinical trials.Under the deal, Serina will issue one million shares of common stock at $10 per share, a significant 120% premium to its Nov. 26 closing price and a 110% premium from Monday’s closing price.The financing is structured in two tranches, with the first $5 million tranche already received on Nov. 27, and the second tranche due by Jan. 31, 2025.&nbsp;The funds will support the advancement of SER-252, an investigational therapy developed using Serina’s proprietary drug optimization technology.&nbsp;Designed to deliver continuous dopaminergic stimulation (CDS), SER-252 aims to mitigate levodopa-related motor complications, such as dyskinesia, while increasing “on time” and reducing “off time” in patients with advanced Parkinson’s disease.&nbsp;The therapy integrates a wearable drug delivery platform, which provides long-acting subcutaneous delivery of CDS without causing skin reactions, enhancing both comfort and convenience for patients.<figure class="image"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SET_sentiment_and_message_volume_on_Dec_3_premarket_ebfe4d174b.png" alt="SET sentiment and message volume on Dec 3 premarket.png" width="1318" height="318"><figcaption>SET sentiment and message volume on Dec 3 premarket as of 8:00 am ET | source: Stocktwits</figcaption></figure>Retail investors were quick to rally behind the stock on Stocktwits, where sentiment turned ‘extremely bullish’ before the opening bell, with message volume surging.&nbsp;<stembedurl>https://stocktwits.com/harry925/message/594787799</stembedurl>Still, Serina’s stock remains down over 67% year-to-date,For updates and corrections, email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-rises-after-upgrade-price-target-hikes/cJ9kq43RhE">Tesla Stock Rises After Massive Price Target Hikes On Trump, AI Factors: Retail’s Charged Up</a>

Under the deal, Serina will issue one million shares of common stock at $10 per share, a 110% premium from Monday’s closing price.

Serina Therapeutics Stock Soars Pre-Market On $10M Equity Deal To Fund Parkinson’s Trials: Retail Sentiment Explodes

The financing is structured in two tranches, with the first $5 million tranche already received on Nov. 27, and the second tranche due by Jan. 31, 2025. 

Serina Therapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the research and development of polymer technology. Its POZ technology is designed to optimize drug delivery to maximize compliance, therapeutic outcomes, safety, and quality of life for patients. It also offers drugs to treat neurological diseases, cancer, and pain. The company was founded by J. Milton Harris and Michael D. Bentley on March 26, 2024 and is headquartered in Huntsville, AL.

SER
Serina Therapeutics Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest SER News

SERSerina Therapeutics Inc.